Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC (NCT06567743)
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (65 Sites)
Showing the first 25 of 65 sites.
- Mayo Clinic Arizona — Phoenix, Arizona
- Arizona Urology Specialty — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Arkansas Urology — Little Rock, Arkansas
- Michael G Oefelein, MD Clinical Trials — Bakersfield, California
- Genesis Research (Greater Los Angeles) — Los Alamitos, California
- Advanced Urology — Los Angeles, California
- Urology Center of Southern California — Murrieta, California
- University of California, Irvine — Orange, California
- Om research — San Diego, California
- University of Southern California — San Diego, California
- Genesis Research (Greater Los Angeles) — Torrance, California
- Colorado Urology — Lakewood, Colorado
- Urology Associates, Lone Tree — Lone Tree, Colorado
- University of Florida — Gainesville, Florida
- Mayo Clinic Florida — Jacksonville, Florida
- Advanced Urology Institute (Solaris) — Largo, Florida
- Advanced Urology Institute — Oxford, Florida
- Advanced Urology Institute - Tallahassee (Solaris) — Tallahassee, Florida
- Emory University — Atlanta, Georgia
- Associated Urological Specialists — Chicago Ridge, Illinois
- Uropartners — Glenview, Illinois
- Urology of Indiana - Carmel — Carmel, Indiana
- Urology of Indiana, LLC (US Urology Partners) — Greenwood, Indiana
- First Urology, PSC — Jeffersonville, Indiana
📞 Contact the Study Coordinator
Phone: (949) 409-3700
Email: Rebecca.Tregunna@cgoncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All High-Risk Non-Muscle-Invasive Bladder Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.